1h Free Analyst Time
The cancer biologics market is forecasted to grow by USD 84.5 billion during 2024-2029, accelerating at a CAGR of 10.7% during the forecast period. The report on the cancer biologics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global incidence of cancer, increased demand for cancer biologics due to emphasis on personalized medicines, and significant therapeutic benefits of cancer biologics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The cancer biologics market is segmented as below:
By Product
- Monoclonal antibodies
- Cell and gene therapy
- Vaccines
- Others
By Route Of Administration
- Injectable
- Oral
By Type
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Others
By Distribution Channel
- Hospitals
- Clinics
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the cancer biologics market covers the following areas:
- Cancer Biologics Market sizing
- Cancer Biologics Market forecast
- Cancer Biologics Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Product
9 Market Segmentation by Route of Administration
10 Market Segmentation by Type
11 Market Segmentation by Distribution Channel
12 Customer Landscape
13 Geographic Landscape
14 Drivers, Challenges, and Opportunity/Restraints
15 Competitive Landscape
16 Competitive Analysis
17 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global cancer biologics market: Amgen Inc., AstraZeneca Plc, Bayer AG, Biocon Ltd., Biogen Inc., Bristol Myers Squibb Co., Celltrion Co. Ltd., Cipla Inc., Dr Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., Lupin Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is untapped potential of cancer biologics in developing countries."
According to the report, one of the major drivers for this market is the rising global incidence of cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Biocon Ltd.
- Biogen Inc.
- Bristol Myers Squibb Co.
- Celltrion Co. Ltd.
- Cipla Inc.
- Dr Reddys Laboratories Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Jazz Pharmaceuticals Plc
- Johnson and Johnson Services Inc.
- Lupin Ltd.
- Merck KGaA
- Novartis AG
- Ono Pharmaceutical Co. Ltd.
- Viatris Inc.
